Hongna Wang
FDA investigator
Appears on 1 document from 2019, mostly at sites in China. Most often cites sampling and testing of in-process materials and drug products (21 CFR 211.110).
- 1
- Documents on file
- 4.0
- Observations per 483
- 2019
- First seen
- 2019
- Most recent
What they cite most
From 4 observations- 21 CFR 211.110Sampling and testing of in-process materials and drug products1
- 21 CFR 211.22Responsibilities of quality control unit1
- 21 CFR 211.67Equipment cleaning and maintenance1
- 21 CFR 211.68Automatic, mechanical, and electronic equipment1
Activity by year
2019: 1
Where
China 1
Is Hongna Wang coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2019-08-02 | 483 Shanghai Desano Bio-Pharmaceutical Co., Ltd.Aug 2, 2019 · Shanghai, China | Shanghai, China | 4 |
About this profile
What does Hongna Wang inspect?
Hongna Wang appears on 1 document on file covering 1 site, mostly in China.
What do they cite most often?
21 CFR 211.110 (sampling and testing of in-process materials and drug products), followed by 21 CFR 211.22 and 21 CFR 211.67.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Hongna Wang is dated Aug 2, 2019.